SecBot SecBot
8-K ·Filed Feb 26, 2026

SLNO

SOLENO THERAPEUTICS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed8mo ago SEC0001193125-26-073209
8-K context-dependent: Items 5.02, 8.01
Actionable Insight • Neutral

Monitor for any unexpected CFO transition risks during the handover period, though the orderly transition and retention of Mackaness as consultant mitigate immediate concerns. Watch for changes in financial guidance or capital allocation strategy under new leadership.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$38.09
T+0 close · Feb 26, 2026 · via day close
Latest settled
+39.17%
T+60 · $53.01
Vs SPY
+31.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $38.09entry
  2. T+1 · 9mo ago +2.57%α +3.03% · $39.07
  3. T+5 · 9mo ago +1.26%α +2.39% · $38.57
  4. T+20 · 8mo ago −16.36%α −9.95% · $31.86
  5. T+60 · 6mo ago +39.17%α +31.42% · $53.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Soleno Therapeutics announced the retirement of CFO James Mackaness and the appointment of Jennifer Fulk as incoming CFO, effective March 2, 2026. Fulk will receive a $525,000 base salary and equity awards totaling 106,860 shares. Mackaness will transition to a consulting role through year-end.

Key Facts

  • Jennifer Fulk appointed CFO effective March 2, 2026
  • James Mackaness retiring, will serve as consultant through December 31, 2026
  • Fulk's compensation: $525,000 base salary, 67,660 stock options, 39,200 RSUs
  • Fulk previously CFO at Talkspace and held executive roles at Eli Lilly
  • No disagreement cited in Mackaness's departure

Financial Impact

Approximately $525,000 annual cash compensation plus equity awards valued at approximately $1.4 million at current stock price (based on 106,860 shares)

compensation expenseshare countequity dilution

Risk Factors

  • Potential disruption during CFO transition
  • Increased compensation expenses
  • Equity dilution from new grants

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-073209
Document: d110816dex101.htm0001193125-26-073209
Document: d110816dex991.htm0001193125-26-073209
Document: 0001193125-26-073209-index-headers.html0001193125-26-073209
Document: 0001193125-26-073209-index.html0001193125-26-073209
Document: 0001193125-26-073209.txt0001193125-26-073209

Track record

10 reports on SLNO

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +2.57% at T+1 after the Feb 26, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Jun 11, 202622w ago Institutional Cluster Bullish 6/10 No price data
  2. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 No price data
  3. May 28, 202624w ago 15-12G Bearish 8/10 No price data
  4. May 28, 202624w ago EFFECT Bearish 5/10 No price data
  5. May 18, 202626w ago 8-K / 25-NSE Bullish 8/10 Entry $53.01 No price data
  6. Apr 7, 202631w ago 8-K Bearish 7/10 Entry $52.35 to $52.62 ▼ −0.52% +4.81% vs SPY
  7. Apr 6, 202632w ago 8-K Bullish 8/10 Entry $52.25 to $52.64 ▲ +0.75% −3.39% vs SPY
  8. Mar 27, 202633w ago Insider Cluster Neutral 3/10 Entry $30.05 to $52.25 ▲ +73.88% +70.01% vs SPY
  9. Feb 26, 202637w ago 8-K Bullish 8/10 Entry $38.09 to $38.57 ▲ +1.26% +2.42% vs SPY
  10. Feb 26, 202637w ago 8-K Neutral 3/10 Viewing Entry $38.09 to $38.57 ▲ +1.26% +2.39% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 6h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026